EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
GILD - Gilead Sciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$151.25
DETAILS
HIGH:
$180.00
LOW:
$123.00
MEDIAN:
$152.50
CONSENSUS:
$151.25
UPSIDE:
1.67%
Stock News
3 Dividend Stocks to Hold for the Next 10 Years
These healthcare leaders are unlikely to suspend their dividend programs.
European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive sc.
Advisors Capital Management LLC Takes Position in Gilead Sciences, Inc. $GILD
Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 31,697 shares of the biopharmaceutical company's stock, valued at approximately $4,005,000. Other institutional investors and hedge funds
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD
Allworth Financial LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 47,192 shares of the biopharmaceutical company's stock, valued at approximately $5,962,000. Several other hedge funds and other institutional
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
59,974 Shares in Gilead Sciences, Inc. $GILD Purchased by Abacus FCF Advisors LLC
Abacus FCF Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 59,974 shares of the biopharmaceutical company's stock, valued at approximately $7,577,000. A number of other hedge
Robbins LLP Encourages ITOC Stockholders Who Lost Money Investing in iTonic Holdings Ltd. to Contact the Firm for Information About Leading the Class Action
San Diego, California--(Newsfile Corp. - August 19, 2026) - Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Pheton Holdings Ltd (NASDAQ: PTHL) (n/k/a iTonic Holdings Ltd. (NASDAQ: ITOC)) securities between September 5, 2024 and July 29, 2025 (the "Class Period").
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022
These stocks can be safe-haven investments to hide out in amid market turmoil.
Aljian Capital Management LLC Invests $568,000 in Gilead Sciences, Inc. $GILD
Aljian Capital Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 4,496 shares of the biopharmaceutical company's stock, valued at approximately $568,000. A number of other institutional investors and hedge funds have also recently
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.
Capital Financial Group Inc. Co. ADV Invests $582,000 in Gilead Sciences, Inc. $GILD
Capital Financial Group Inc. Co. ADV bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,605 shares of the biopharmaceutical company's stock, valued at approximately $582,000. A number of other large investors have
AMG National Trust Bank Purchases Shares of 26,675 Gilead Sciences, Inc. $GILD
AMG National Trust Bank purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,675 shares of the biopharmaceutical company's stock, valued at approximately $3,370,000. Other institutional investors have also modified their
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected 2027–2028. ASMB's partnership with Gilead on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.
BIP Wealth LLC Purchases New Holdings in Gilead Sciences, Inc. $GILD
BIP Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 4,520 shares of the biopharmaceutical company's stock, valued at approximately $571,000. Other hedge funds and other institutional investors
Abundance Wealth Counselors Grows Stake in Gilead Sciences, Inc. $GILD
Abundance Wealth Counselors boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 93.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,139 shares of the biopharmaceutical company's stock after purchasing an additional 10,710 shares during the quarter. Abundance Wealth
Benjamin Edwards Inc. Has $15.86 Million Stock Holdings in Gilead Sciences, Inc. $GILD
Benjamin Edwards Inc. trimmed its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 5.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 125,525 shares of the biopharmaceutical company's stock after selling 6,539 shares during the quarter. Benjamin Edwards Inc.'s holdings in
Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
A U.S. Court of Appeals on Thursday upheld a preliminary injunction against several AFPs and related businesses. The ruling could pave the way for the growing alternative funding programs industry to shrink.
First Bank & Trust Lowers Stock Position in Gilead Sciences, Inc. $GILD
First Bank and Trust decreased its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 22.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,831 shares of the biopharmaceutical company's stock after selling 6,178 shares during the quarter.
Price Targets
Gilead price target lowered to $150 from $156 at Truist
$150.00
(was $132.75)
Truist Financial
Gilead price target raised to $123 from $120 at RBC Capital
$123.00
(was $135.25)
RBC Capital
Gilead price target lowered to $145 from $155 at Barclays
$145.00
(was $134.32)
Barclays
Gilead price target lowered to $165 from $166 at Morgan Stanley
$165.00
(was $131.23)
Morgan Stanley
Gilead downgraded to Market Perform from Outperform at Leerink
$127.00
(was $133.21)
Daina Graybosch
·
Leerink Partners
Gilead price target lowered to $166 from $168 at Morgan Stanley
$166.00
(was $136.36)
Morgan Stanley
Gilead price target lowered to $120 from $122 at RBC Capital
$120.00
(was $129.61)
Brian Abrahams
·
RBC Capital
HSBC Upgrades Gilead Sciences (GILD) to Buy
$155.00
(was $131.27)
Rajesh Kumar
·
HSBC
RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
$122.00
(was $134.43)
Brian Abrahams
·
RBC Capital
Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation
$165.00
(was $130.55)
Michael Okunewitch
·
Maxim Group
Gilead price target lowered to $168 from $175 at Morgan Stanley
$168.00
(was $131.33)
Morgan Stanley
Gilead price target raised to $157 from $155 at Truist
$157.00
(was $132.03)
Truist Financial
Gilead price target raised to $175 from $171 at Morgan Stanley
$175.00
(was $140.34)
Morgan Stanley
Gilead price target raised to $155 from $152 at Truist
$155.00
(was $141.54)
Gregory Renza
·
Truist Financial
Jefferies Starts Gilead Sciences (GILD) at Buy
$180.00
(was $146.94)
Akash Tewari
·
Jefferies
Gilead initiated with an Equal Weight at Barclays
$155.00
(was $151.12)
Barclays
Gilead price target raised to $170 from $140 at Mizuho
$170.00
(was $152.74)
Mizuho Securities
Gilead price target raised to $175 from $155 at UBS
$175.00
(was $155.27)
UBS
Gilead price target raised to $177 from $140 at Scotiabank
$177.00
(was $155.29)
Louise Chen
·
Scotiabank
Gilead Sciences (GILD) PT Raised to $160 at Bernstein SocGen Group
$160.00
(was $155.45)
Courtney Breen
·
Bernstein